National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anti-CD33 monoclonal antibody-DM4 conjugate AVE9633
An immunoconjugate consisting of the humanized monoclonal antibody huMy9-6 conjugated to the cytotoxic maytansinoid DM4 with potential antineoplastic activity. The monoclonal antibody portion of anti-CD33 monoclonal antibody-DM4 conjugate AVE9633 specifically binds to the cell surface antigen CD33 expressed on myeloid leukemia cells; upon internalization, the DM4 moiety is released, binds tubulin, and disrupts microtubule assembly/disassembly dynamics, resulting in the inhibition of cell division and cell growth in myeloid leukemia cells that express CD33. CD33 is expressed on normal non-pluripotent hematopoietic stem cells as well as on myeloid leukemia cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Code name:AVE9633



Previous:anti-CD200 monoclonal antibody ALXN6000, anti-CD22 immunotoxin CAT-8015, anti-CD3 immunotoxin A-dmDT390-bisFv(UCHT1), anti-CD30 monoclonal antibody MDX-1401, anti-CD30 monoclonal antibody XmAb2513
Next:anti-CD37 single-chain polypeptide TRU-016, anti-CD38 monoclonal antibody, anti-CD45 monoclonal antibody, anti-CD45 monoclonal antibody AHN-12, anti-CD70 monoclonal antibody MDX-1411

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov